Lenalidomide for relapsed or refractory multiple myeloma
We report the activity of lenalidomide (revlimide – R), lenalidomide plus dexamethasone (Rd), lenalidomide plus bortezomib plus dexamethasone (RVd) in 34 patients with relapsed and refractory myeloma. For patients who received lenalidomide the overall response rate was 70.5 %. 38 % patients achieved...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/64 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689819564736512 |
|---|---|
| author | S. S. Bessmeltsev1 E. V. Kariagina L. V. Stelmashenko G. N. Salogub E. R. Machulaitene K. M. Abdulkadyrov N. A. Kotova I. I. Kostroma N. V. Medvedeva L. I. Krylova E. Yu. Ilushkina |
| author_facet | S. S. Bessmeltsev1 E. V. Kariagina L. V. Stelmashenko G. N. Salogub E. R. Machulaitene K. M. Abdulkadyrov N. A. Kotova I. I. Kostroma N. V. Medvedeva L. I. Krylova E. Yu. Ilushkina |
| author_sort | S. S. Bessmeltsev1 |
| collection | DOAJ |
| description | We report the activity of lenalidomide (revlimide – R), lenalidomide plus dexamethasone (Rd), lenalidomide plus bortezomib plus dexamethasone (RVd) in 34 patients with relapsed and refractory myeloma. For patients who received lenalidomide the overall response rate was 70.5 %. 38 % patients achieved very good partial response (VGPR) + complete response (CR). Median overall survival (OS) was 48 months. Lenalidomide may overcome the poor prognostic impact of various factors, particularly elevated beta (2)-microglobulin. Lenalidomide is highly active in elderly patients (> 65 years). Significantly increased OS with a lenalidomide-based induction and lenalidomide maintenance therapy was revealed. The median duration of the overall response without lenalidomide maintenance therapy was 10 months. The median duration of the overall response with lenalidomide maintenance therapy was 20 months (р < 0,05). Median OS with lenalidomide maintenance therapy was not reached. Median OS without lenalidomide maintenance therapy was 36 months (р < 0.05). Side effects were predictable and manageable. The most common adverse events reported were neutropenia (38.3 %) and thrombocytopenia (23.7 %). Serious adverse events were rare. |
| format | Article |
| id | doaj-art-796ac156b3be4be8a03308e5ceb7b1e0 |
| institution | DOAJ |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2014-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-796ac156b3be4be8a03308e5ceb7b1e02025-08-20T03:21:30ZrusABV-pressОнкогематология1818-83462413-40232014-07-017161410.17650/1818-8346-2012-7-1-6-1479Lenalidomide for relapsed or refractory multiple myelomaS. S. Bessmeltsev10E. V. Kariagina1L. V. Stelmashenko2G. N. Salogub3E. R. Machulaitene4K. M. Abdulkadyrov5N. A. Kotova6I. I. Kostroma7N. V. Medvedeva8L. I. Krylova9E. Yu. Ilushkina10Russian Research Institute of Hematology and TransfusiologyCity Hospital 15Russian Research Institute of Hematology and TransfusiologyCity Hospital 15Pavlov State Medical University of St.-PetersburgRussian Research Institute of Hematology and TransfusiologyCity Hospital 31Russian Research Institute of Hematology and TransfusiologyCity Hospital 31City Hospital 15City Hospital 15We report the activity of lenalidomide (revlimide – R), lenalidomide plus dexamethasone (Rd), lenalidomide plus bortezomib plus dexamethasone (RVd) in 34 patients with relapsed and refractory myeloma. For patients who received lenalidomide the overall response rate was 70.5 %. 38 % patients achieved very good partial response (VGPR) + complete response (CR). Median overall survival (OS) was 48 months. Lenalidomide may overcome the poor prognostic impact of various factors, particularly elevated beta (2)-microglobulin. Lenalidomide is highly active in elderly patients (> 65 years). Significantly increased OS with a lenalidomide-based induction and lenalidomide maintenance therapy was revealed. The median duration of the overall response without lenalidomide maintenance therapy was 10 months. The median duration of the overall response with lenalidomide maintenance therapy was 20 months (р < 0,05). Median OS with lenalidomide maintenance therapy was not reached. Median OS without lenalidomide maintenance therapy was 36 months (р < 0.05). Side effects were predictable and manageable. The most common adverse events reported were neutropenia (38.3 %) and thrombocytopenia (23.7 %). Serious adverse events were rare.https://oncohematology.abvpress.ru/ongm/article/view/64multiple myelomalenalidomidecomplete responsevery good partial responseoverall survival |
| spellingShingle | S. S. Bessmeltsev1 E. V. Kariagina L. V. Stelmashenko G. N. Salogub E. R. Machulaitene K. M. Abdulkadyrov N. A. Kotova I. I. Kostroma N. V. Medvedeva L. I. Krylova E. Yu. Ilushkina Lenalidomide for relapsed or refractory multiple myeloma Онкогематология multiple myeloma lenalidomide complete response very good partial response overall survival |
| title | Lenalidomide for relapsed or refractory multiple myeloma |
| title_full | Lenalidomide for relapsed or refractory multiple myeloma |
| title_fullStr | Lenalidomide for relapsed or refractory multiple myeloma |
| title_full_unstemmed | Lenalidomide for relapsed or refractory multiple myeloma |
| title_short | Lenalidomide for relapsed or refractory multiple myeloma |
| title_sort | lenalidomide for relapsed or refractory multiple myeloma |
| topic | multiple myeloma lenalidomide complete response very good partial response overall survival |
| url | https://oncohematology.abvpress.ru/ongm/article/view/64 |
| work_keys_str_mv | AT ssbessmeltsev1 lenalidomideforrelapsedorrefractorymultiplemyeloma AT evkariagina lenalidomideforrelapsedorrefractorymultiplemyeloma AT lvstelmashenko lenalidomideforrelapsedorrefractorymultiplemyeloma AT gnsalogub lenalidomideforrelapsedorrefractorymultiplemyeloma AT ermachulaitene lenalidomideforrelapsedorrefractorymultiplemyeloma AT kmabdulkadyrov lenalidomideforrelapsedorrefractorymultiplemyeloma AT nakotova lenalidomideforrelapsedorrefractorymultiplemyeloma AT iikostroma lenalidomideforrelapsedorrefractorymultiplemyeloma AT nvmedvedeva lenalidomideforrelapsedorrefractorymultiplemyeloma AT likrylova lenalidomideforrelapsedorrefractorymultiplemyeloma AT eyuilushkina lenalidomideforrelapsedorrefractorymultiplemyeloma |